أستونيا - الإستونية - Ravimiamet

glaxosmithkline biologicals - gripiviirus, inaktiveeritud, tükeldatud viirus või pinnaantigeen - süstesuspensioon - 1annus 0.5ml 20tk; 1annus 0.5ml 10tk

أستونيا - الإستونية - Ravimiamet

fresenius kabi oncology plc - gemtsitabiin - infusioonilahuse kontsentraat - 40mg 1ml 50ml 1tk; 40mg 1ml 25ml 1tk; 40mg 1ml 5ml 1tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

takeda pharma a/s - fentanüül citrate - pain; cancer - valuvaigistid - instanyl on näidustatud läbimurdevalu raviks täiskasvanutel, kes juba saavad säilitusravi opioididega kroonilise vähivalu. läbimurrevalu on vahelduv valu ägenemine, mis esineb muidu kontrollitud püsiva valu taustal.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

roche registration gmbh - metoksü polüetüleenglükool-epoetin beta - anemia; kidney failure, chronic - antianemilised preparaadid - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - kõhu neoplasmid - antineoplastilised ained - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

bial portela & companhia s.a. - opikapoon - parkinsoni tõbi - parkinsoni tõve ravimid - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - ravi täiskasvanud patsientidel, kellel on tüüp-2 diabeet:jentadueto on märgitud lisandina toitumise ja treeningu parandamiseks glycaemic kontrolli täiskasvanud patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin üksi, või need, kes on juba ravitakse kombinatsioon linagliptin ja metformiin. jentadueto on näidustatud kombinatsioonis sulphonylurea i. kolmekordne kombineeritud ravi) lisandina, et toitumine ja treening täiskasvanud patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - trajenta on näidustatud ravi 2. tüüpi suhkurtõve parandada glycaemic kontrolli täiskasvanud:kui monotherapyin patsientidel, ebapiisavalt kontrollitud dieet ja füüsiline koormus üksi ning kellele metformiin ei sobi tõttu, sallimatus, või vastunäidustatud tingitud neerupuudulikkus;. kui koostisega therapyin koos metformiin, kui dieedi ja füüsilise koormuse pluss metformiin üksi ei taga piisavat kontrolli glycaemic. koos sulphonylurea ja metformiin, kui dieedi ja füüsilise koormuse pluss dual ravi nende ravimitega ei taga piisavat kontrolli glycaemic. koos insuliini või ilma metformiin, kui seda raviskeemi üksi, koos dieedi ja füüsilise koormuse, ei anna adekvaatset kontrolli glycaemic.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - letermovir - tsütomegaloviiruse infektsioonid - viirusevastased ravimid süsteemseks kasutamiseks - prevymis on näidustatud tsütomegaloviiruse (cmv) reaktiveerumine ja täiskasvanud cmv-seropositiivsete saajate [r +] allogeenset hematopoeetiliste tüvirakkude transplantatsioon (htt) haiguse. tuleks arvesse võtta ametlikke juhiseid sobiva kasutamise kohta viirusevastane ained.